Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 46.50 GBp
Change Today +1.00 / 2.20%
Volume 5.7K
As of 12:35 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

vernalis plc (VER) Snapshot

Open
45.75 GBp
Previous Close
45.50 GBp
Day High
46.50 GBp
Day Low
45.75 GBp
52 Week High
12/5/14 - 53.00 GBp
52 Week Low
06/3/14 - 28.75 GBp
Market Cap
205.7M
Average Volume 10 Days
116.2K
EPS TTM
-0.0060 GBp
Shares Outstanding
442.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERNALIS PLC (VER)

Related News

No related news articles were found.

vernalis plc (VER) Related Businessweek News

No Related Businessweek News Found

vernalis plc (VER) Details

Vernalis plc, a research and development stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Frovatriptan, a selective 5-HT1B/1D receptor agonist for an acute oral treatment of migraine headache and its associated symptoms. The company also has a development and licensing agreement to develop approximately six extended-release liquid formulations of short-acting prescription cough cold products. In addition, it is developing V158866, a fatty acid amide hydrolase inhibitor that is in Phase II proof-of-concept (POC) clinical trial for the treatment of various pain and other CNS disorders; and V81444, an adenosine A2A receptor antagonist, which is in Phase Ib/II POC clinical trial for the treatment of Parkinson’s disease and other neurological disorders. Further, the company is developing AUY922, an intravenous Hsp90 inhibitor for treating a range of cancers in Phase I and Phase II clinical trial; CHR2797, an oral aminopeptidase inhibitor for acute myeloid leukaemia and myelodysplastic syndrome under Phase II trial; V158411 molecule and Servier 1, which are in pre-clinical stage for treating cancer; and RPL554, a novel long-acting inhibitor under Phase II clinical trial for treating inflammatory respiratory diseases. The company has collaborations with Asahi Kasei Pharma; Endo Pharmaceuticals Inc; Genentech Inc; H. Lundbeck A/S; Menarini International Operations Luxembourg SA; Novartis Institute for Biomedical Research Inc; Novartis Pharma AG; Servier Research Group; and Tris Pharma Inc. Vernalis plc was incorporated in 1988 and is headquartered in Winnersh, the United Kingdom.

Founded in 1988

vernalis plc (VER) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: 610.0K GBP
Chief Financial Officer and Director
Total Annual Compensation: 417.0K GBP
Compensation as of Fiscal Year 2013.

vernalis plc (VER) Key Developments

Vernalis plc Licenses Proprietary Adenosine Receptor Antagonist Technology

Vernalis plc announced that it has licensed exclusive, worldwide rights in its adenosine receptor antagonist programme, including the lead drug candidate, V81444, for use in all therapeutic applications to a well-funded, US-based biotechnology company. The transaction includes a $1 million upfront payment and has the potential for Vernalis to earn over $200 million subject to development, regulatory and sales milestones being achieved. In addition there are single digit royalties payable if a product reaches the market, with the potential to reach double digit royalties in certain circumstances. V81444 is a patented molecule that has been evaluated in phase I and II clinical trials under an IND in the US. Its initial development was focused on ADHD and other neurological diseases.

Vernalis plc Reports Unaudited Consolidated Earnings Results for the Six Months and Twelve Months Ended December 31, 2014

Vernalis plc reported unaudited consolidated earnings results for the six months and twelve months ended December 31, 2014. Revenue was £5.7 million compared to £6.5 million for the same period a year ago. Operating loss before exceptional items was £4.3 million compared to £4.7 million a year ago. Profit for the period was £1.7 million, compared to loss of £8.2 million for the same period a year ago, including a £4.5 million unrealized foreign exchange gain compared to £5.3 million loss a year ago, due to the weakening of sterling against the US dollar. Profit before income tax was £293,000 compared to loss of £8,845,000 a year ago. Profit per basic and diluted share was 0.4 pence compared to loss of 1.8 pence. Net cash used in operating activities £0.313 million compared to £3.153 million a year ago. Purchase of property, plant and equipment was of £0.553 million compared to £3.153 million a year ago. For twelve months, Revenue was £11.9 million compared to £14.1 million a year ago. Operating loss before exceptional items was £8.1 million compared to £7.3 million a year ago. Loss for the period was £2.9 million, compared to £4.0 million a year ago, including a £2.8 million unrealized foreign exchange gain compared to £0.9 million loss a year ago, due to the weakening of sterling against the US dollar. Loss before income tax was £5.237 million compared to £6.274 million a year ago. Loss per basic and diluted share was 0.7 pence compared to 0.9 pence. Net cash used in operating activities £3.307 million compared to £1.557 million a year ago. Purchase of property, plant and equipment was of £0.683 million compared to £0.646 million a year ago.

Vernalis plc to Report Fiscal Year 2014 Results on Feb 10, 2015

Vernalis plc announced that they will report fiscal year 2014 results at 7:00 AM, GMT Standard Time on Feb 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VER:LN 46.50 GBp +1.00

VER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Richter Gedeon Nyrt 3,952 -68.00
Endo International PLC $90.04 USD +2.23
Grifols SA €39.39 EUR +0.135
STADA Arzneimittel AG €30.85 EUR +0.52
UCB SA €68.49 EUR +0.87
View Industry Companies
 

Industry Analysis

VER

Industry Average

Valuation VER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.0x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERNALIS PLC, please visit www.vernalis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.